163 related articles for article (PubMed ID: 16360718)
1. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it.
Hait WN; Yang JM
Semin Oncol; 2005 Dec; 32(6 Suppl 7):S16-21. PubMed ID: 16360718
[TBL] [Abstract][Full Text] [Related]
2. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).
Lee JJ; Swain SM
Semin Oncol; 2005 Dec; 32(6 Suppl 7):S22-6. PubMed ID: 16360719
[TBL] [Abstract][Full Text] [Related]
3. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR).
Fojo AT; Menefee M
Semin Oncol; 2005 Dec; 32(6 Suppl 7):S3-8. PubMed ID: 16360716
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis.
Clarke R; Leonessa F; Trock B
Semin Oncol; 2005 Dec; 32(6 Suppl 7):S9-15. PubMed ID: 16360717
[TBL] [Abstract][Full Text] [Related]
5. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR).
Lee CH
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):43-52. PubMed ID: 14754411
[TBL] [Abstract][Full Text] [Related]
6. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.
Litman T; Druley TE; Stein WD; Bates SE
Cell Mol Life Sci; 2001 Jun; 58(7):931-59. PubMed ID: 11497241
[TBL] [Abstract][Full Text] [Related]
7. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
8. Non-P-glycoprotein drug export mechanisms of multidrug resistance.
List AF
Semin Hematol; 1997 Oct; 34(4 Suppl 5):20-4. PubMed ID: 9408957
[TBL] [Abstract][Full Text] [Related]
9. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
10. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
Brooks TA; O'Loughlin KL; Minderman H; Bundy BN; Ford LA; Vredenburg MR; Bernacki RJ; Priebe W; Baer MR
Invest New Drugs; 2007 Apr; 25(2):115-22. PubMed ID: 17072745
[TBL] [Abstract][Full Text] [Related]
11. Reversing agents for ATP-binding cassette drug transporters.
Lee CH
Methods Mol Biol; 2010; 596():325-40. PubMed ID: 19949930
[TBL] [Abstract][Full Text] [Related]
12. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
[TBL] [Abstract][Full Text] [Related]
13. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
[TBL] [Abstract][Full Text] [Related]
14. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
Erić S; Kalinić M; Ilić K; Zloh M
SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance of tumor cells.
Szabó D; Keyzer H; Kaiser HE; Molnár J
Anticancer Res; 2000; 20(6B):4261-74. PubMed ID: 11205256
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators.
Brooks TA; Kennedy DR; Gruol DJ; Ojima I; Baer MR; Bernacki RJ
Anticancer Res; 2004; 24(2A):409-15. PubMed ID: 15152938
[TBL] [Abstract][Full Text] [Related]
17. Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.
Coley HM; Labeed FH; Thomas H; Hughes MP
Biochim Biophys Acta; 2007 Apr; 1770(4):601-8. PubMed ID: 17270349
[TBL] [Abstract][Full Text] [Related]
18. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
20. Microparticles and their emerging role in cancer multidrug resistance.
Gong J; Jaiswal R; Mathys JM; Combes V; Grau GE; Bebawy M
Cancer Treat Rev; 2012 May; 38(3):226-34. PubMed ID: 21757296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]